ViewRay, Inc. (NASDAQ:VRAY) Q4 2022 Earnings Call Transcript

Scott Drake : Yeah. I think it sure does. I mean, whenever you get this kind of data that is this compelling in a publication that is this widespread, it is helpful to us. On an anonymized basis, I would tell you that multiple MRIdian customers are seeing demand increase as a consequence of the data that we have here in MIRAGE specifically. I think the publication helps it. I think that’s broadly true, Brandon. We have customers who are seeing when they share with patients the full therapeutic set of options, whether you’re talking about surgery or radiation therapy, they would tell you that more and more of their patients are choosing the non-invasive MRIdian option. And I think that has a significant degree to do with the clinical data that we have.

I think there’s another component of it that is market awareness-based from one patient to another, patients talking to one another. That is having increased demand effect at multiple MRIdian customers. And I think that is a component of our strategy that we’re talking about here, the innovation pipeline enabling the clinical pipeline. Those two allowing us to amplify the effect with market awareness, and all of that driving therapy adoption. I think that is the ViewRay story and ultimately, patients will write it. I have seen personally firsthand that when patients are aware that highly effective, short course, virtually side effect-free therapy, when they’re aware that, that therapy is available, they’ll demand it and travel for it, and we are experiencing that as we speak.

Unidentified Analyst: Thanks for the color. And thanks for taking our questions.

Scott Drake : Thanks, Brandon.

Operator: There are no further questions at this time. This concludes today’s conference call. Thank you for your participation. You may now disconnect.